|1.||Sima, Anders A F: 19 articles (10/2009 - 09/2003)|
|2.||Kaaks, Rudolf: 17 articles (11/2014 - 02/2003)|
|3.||Pollak, Michael N: 14 articles (01/2015 - 04/2005)|
|4.||Fuchs, Charles S: 13 articles (01/2015 - 01/2005)|
|5.||Rinaldi, Sabina: 13 articles (04/2013 - 02/2003)|
|6.||Ma, Jing: 12 articles (01/2015 - 04/2004)|
|7.||Riboli, Elio: 12 articles (11/2014 - 04/2003)|
|8.||Marx, Nikolaus: 11 articles (09/2015 - 03/2004)|
|9.||Hankinson, Susan E: 11 articles (10/2013 - 09/2003)|
|10.||Giovannucci, Edward: 11 articles (04/2013 - 02/2004)|
|1.||Type 1 Diabetes Mellitus (Autoimmune Diabetes)
07/01/1998 - "To investigate the role of puberty on spontaneous clinical remission and on secretion of residual C-peptide during the first year of type 1 diabetes mellitus, we studied 77 pre-pubertal, 39 pubertal and 41 post-pubertal type 1 diabetic patients. "
01/01/1998 - "In addition, replacement of C-peptide during a period of 1-3 months has been shown to improve renal function as well as autonomic and sensory nerve function in IDDM patients. "
01/01/2007 - "At present, in view of numerous studies concerning its structure, membrane binding and biological functions, C-peptide seems to constitute a crucial role in the pathogenesis of complications in diabetes mellitus type 1 (DM1). "
04/01/2005 - "Recent studies have demonstrated that replacement of C-peptide to normal physiological concentrations in IDDM patients either on a short-term basis (1-3 hours) or on a prolonged administration (1-3 months) was accompanied by improvements in renal glomerular and tubular function. "
05/01/2004 - "The study included 20 participants with C-peptide-deficient Type 1 diabetes mellitus. "
01/01/2015 - "Since insulin resistance is genetically determined and observed in type 1 diabetes, the study was designed to elucidate an involvement of Ala 12 Pro PPARg2 gene polymorphism in residual C-peptide secretion and BMI variation in children with type 1 diabetes. "
09/01/2015 - "Homeostatic model assessment of insulin resistance, C-peptide and glycemic variability were assessed before and after therapy. "
01/01/2015 - "Thus, it is likely that PPARg2 gene polymorphism and/or the genetically determined insulin resistance may be associated with residual C-peptide secretion and involve excessive BMI in type 1 diabetes. "
01/01/2015 - "Increased betatrophin level in obese subjects is correlated with an increase in C-peptide level; which is possibly caused by the increased insulin resistance. "
01/01/2013 - "Insulinogenic and Disposition Indexes were 35%-97% higher in AI and each subgroup (p<0.008 vs.CON), whereas C-peptide-derived Adaptation Index, compensating for insulin-resistance, was comparable between AI, subgroups, and CON. "
|3.||Type 2 Diabetes Mellitus (MODY)
01/01/1993 - "The peritubular uptake of C-peptide was significantly lower in NIDDM, while the fractional clearance of C-peptide was significantly higher. "
02/01/2013 - "At the same time, C-peptide at the concentrations above physiological may demonstrate pro-inflammatory effects on the endothelial cells and cause atherosclerotic changes in the vessels, which should be considered in the study of pathogenic mechanisms of complications of type 2 diabetes mellitus, where the level of C peptide is increased, as well as in the development of approaches for C-peptide application in clinic. "
10/01/2012 - "This study aimed to investigate whether stimulated C-peptide is associated with microvascular complications in type 2 diabetes mellitus (DM). "
02/01/2011 - "The present study was designed to examine whether the basal C-peptide levels correlate with cardiovascular risk in type 2 diabetes mellitus (T2DM) patients. "
10/01/1992 - "The goal of the study was to provide cross-sectional descriptive data on the response of C-peptide to a vigorous meal stimulus in a population-based sample of nondiabetic adults compared with a population-based sample of adults with NIDDM. "
01/01/2012 - "The objective of this study was to determine whether C-peptide affords protection to renal microvascular endothelial cell mitochondria during hyperglycemia. "
03/01/2011 - "At the sixth postoperative month, HbA1c, FPG, 2-h PPG, and C-peptide level measured 6.7%, 144 mg/dl, 203 mg/dl, and 2.18 ng/ml. This preliminary study demonstrated the resolution of hyperglycemia in 70% of non-obese T2DM patients (BMI 25-30 kg/m(2)). "
11/01/2013 - "These findings highlight a novel mechanism by which C-peptide activates AMPKα and protects against hyperglycemia-induced vasculopathy. "
11/01/2013 - "C-peptide replacement therapy normalized hyperglycemia-induced AMPKα dephosphorylation, ROS generation, and mitochondrial disorganization in aorta of diabetic mice. "
01/01/2013 - "Thus, C-peptide protects endothelial cells from hyperglycemia-induced apoptotic cell death by inhibiting intracellular ROS-mediated activation of TG2. "
|5.||Weight Loss (Weight Reduction)
02/01/2012 - "There was a marked reduction in C-peptide after a significant weight reduction 1 year after surgery with a T2DM remission rate of 78.0%. "
10/01/2015 - "In univariate analysis, non-obese patients who had T2DM remission after surgery were heavier and had a wider waist, higher C-peptide levels, shorter disease duration, more weight loss, and higher ABCD score than those without remission. "
06/01/1990 - "The metabolic clearance of C-peptide, assessed by decay analysis after bolus injection of biosynthetic human C-peptide, was not changed by weight loss (0.143 +/- 0.009 L/min.m2 vs. 0.137 +/- 0.010 L/min.m2). "
10/01/2010 - "The aim of this study was to assess the concentration of C-peptide and selected parameters of lipid profile in prepubertal obese children before and after weight reduction therapy. "
05/01/2013 - "Early-onset T2DM, better weight loss, and greater C-peptide levels were predictors of success after surgery. "
|4.||Blood Glucose (Blood Sugar)
|6.||Insulin-Like Growth Factor I (IGF-1)
|1.||Transplantation (Transplant Recipients)
|5.||Female Contraceptive Devices (Vaginal Ring)